

---

## WilmerHale Reps MacroGenics in Global Collaboration and Licensing Agreement With Incyte

OCTOBER 26, 2017

MacroGenics, Inc. and Incyte Corporation announced that they have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.

The WilmerHale team counseling MacroGenics was led by [Steve Singer](#) and includes [Steve Barrett](#), [Ritu Gupta](#) and [Jenna Ventrino](#).

[Read MacroGenics' press release](#) for more information.